@article{84c84b6988a44459ad4486dea7af3f6c,
title = "Induction chemotherapy and molecular MRD influence outcomes in KMT2A-rearranged AML",
abstract = "We analyzed 217 patients with KMT2A-rearranged acute myeloid leukemia (AML) in 2 large sequential randomized trials. Those randomized to FLAG-Ida (fludarabine, cytarabine, granulocyte colony-stimulating factor, idarubucin) had markedly lower rates of relapse than other chemotherapy regimens. Molecular measurable residual disease assessment after cycle 2 was strongly prognostic for relapse and death. The trials were registered at the ISRCTN Registry as AML17 ISRCTN55675535 and AML19 ISRCTN78449203.",
keywords = "Humans, Leukemia, Myeloid, Acute/genetics, Myeloid-Lymphoid Leukemia Protein/genetics, Histone-Lysine N-Methyltransferase/genetics, Male, Female, Middle Aged, Gene Rearrangement, Adult, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Neoplasm, Residual/genetics, Aged, Induction Chemotherapy, Cytarabine/administration & dosage, Prognosis, Treatment Outcome, Young Adult, Adolescent, Vidarabine/analogs & derivatives, Granulocyte Colony-Stimulating Factor/administration & dosage",
author = "Jad Othman and Nicola Potter and Freeman, {Sylvie D.} and Nicholas McCarthy and Jelena Jovanovic and Manohursingh Runglall and Joanna Canham and Ian Thomas and Sean Johnson and Amanda Gilkes and Jamie Cavenagh and Panagiotis Kottaridis and David Taussig and Claire Arnold and Claire Hemmaway and Dominic Culligan and Overgaard, {Ulrik Malthe} and Mike Dennis and Burnett, {Alan K.} and Russell, {Nigel H.} and Richard Dillon",
note = "Publisher Copyright: {\textcopyright} 2025 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.",
year = "2025",
month = oct,
day = "9",
doi = "10.1182/blood.2025029556",
language = "English",
volume = "146",
pages = "1862--1867",
journal = "Blood",
issn = "0006-4971",
publisher = "Elsevier BV",
number = "15",
}